Cardlytics (CDLX) News Today

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) COO Amit Gupta sold 22,699 shares of the firm's stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $8.66, for a total value of $196,573.34. Following the sale, the chief operating officer now directly owns 150,569 shares of the company's stock, valued at $1,303,927.54. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) insider Nicholas Hollmeyer Lynton sold 5,956 shares of the business's stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $7.95, for a total value of $47,350.20. Following the transaction, the insider now owns 78,593 shares of the company's stock, valued at approximately $624,814.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Shares of Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) have received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has

Northland Capmk upgraded Cardlytics to a "strong-buy" rating in a report on Tuesday.

General Equity Holdings LP raised its stake in Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 31.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 624,058 shares of the company's stock after acquiri

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CEO Karim Saad Temsamani sold 43,129 shares of the business's stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total transaction of $373,065.85. Following the transaction, the chief executive officer now directly owns 385,530 shares of the company's stock, valued at approximately $3,334,834.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 6,550,000 shares, a growth of 17.0% from the April 30th total of 5,600,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is presently 3.5 days.

Craig Hallum cut their price target on Cardlytics from $18.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday.

Cardlytics (NASDAQ:CDLX) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588904)

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) COO Amit Gupta sold 23,416 shares of the company's stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $11.91, for a total transaction of $278,884.56. Following the completion of the transaction, the chief operating officer now owns 122,676 shares in the company, valued at $1,461,071.16. The sale was disclosed in a filing with the SEC, which is available through this link.

Vanguard Group Inc. boosted its position in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 13.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,011,705 shares of the company's stock after buying a

Cardlytics (NASDAQ:CDLX) Stock Price Up 4.7%

Baillie Gifford & Co. cut its position in Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 9.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 946,058 shares of the company's stock after selling 103,390 shares during the period. Baillie Gifford & Co. owned a

Needham & Company LLC boosted their price target on Cardlytics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Tuesday.

Assenagon Asset Management S.A. boosted its stake in Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 540.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,351 shares of the company's stock after acquiring an

Cardlytics (NASDAQ:CDLX) Trading Up 5.3%

Cardlytics (NASDAQ:CDLX) Stock Price Down 3.7% on Insider Selling

Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) insider Nicholas Hollmeyer Lynton sold 12,460 shares of the business's stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total transaction of $170,577.40. Following the completion of the transaction, the insider now directly owns 71,355 shares of the company's stock, valued at $976,849.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.